Literature DB >> 16669405

Cancer incidence and causes of death among total hip replacement patients: a review based on Nordic cohorts with a special emphasis on metal-on-metal bearings.

T I Visuri1, E Pukkala, P Pulkkinen, P Paavolainen.   

Abstract

All patients with total hip arthroplasty (THA) are exposed to soluble or particulate forms of Co and Cr. Adverse effects of these wear products are not known. Data from Nordic registries is used to estimate adverse effects on a large scale, based mostly on metal-on-polyethylene bearings. Cancer incidence was in line with the general population when the patients were operated on for all indications and significantly decreased when the indication was primary osteoarthritis. Stomach cancer and colorectal cancers were significantly reduced and prostate cancer and skin melanoma significantly increased. There was no significant excess of cancer in target organs, i.e. liver, kidney, or haematopoietic cancers. THA patients had reduced mortality and extended life expectancy compared with standard Nordic populations. All-site cancer incidence of the first-generation metal-on-metal McKee-Farrar patients operated on for primary osteoarthritis was in line with the general population after follow-up for up to 28 years. General mortality of these patients was also reduced and they also had an extended life expectancy. Temporary increases in haematopoietic cancers at different follow-up periods were seen in some cohorts. This malignancy deserves a special record linkage monitoring while large numbers of young patients are provided with the second generation of metal-on-metal prostheses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669405     DOI: 10.1243/095441105X63282

Source DB:  PubMed          Journal:  Proc Inst Mech Eng H        ISSN: 0954-4119            Impact factor:   1.617


  17 in total

Review 1.  Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis.

Authors:  Ryan W Dellinger; Feng Liu-Smith; Frank L Meyskens
Journal:  J Photochem Photobiol B       Date:  2014-06-20       Impact factor: 6.252

2.  Concordance between laboratories in metal ion testing in patients with metal-on-metal hip implants.

Authors:  Raghav Saini; Pam Railton; Jessica Boyd; Hossein Sadrzadeh; James N Powell
Journal:  Can J Surg       Date:  2019-02-01       Impact factor: 2.089

3.  The withdrawn ASR™ THA and hip resurfacing systems: how have our patients fared over 1 to 6 years?

Authors:  Kevin T Hug; Tyler S Watters; Thomas P Vail; Michael P Bolognesi
Journal:  Clin Orthop Relat Res       Date:  2013-02       Impact factor: 4.176

4.  A painful soft tissue mass secondary to impingement of a metal on polyethylene bearing total hip arthroplasty.

Authors:  Griffiths-Jones William; Williams Daniel
Journal:  BMJ Case Rep       Date:  2014-05-20

Review 5.  Development of malignant lymphoma after metal-on-metal hip replacement: a case report and review of the literature.

Authors:  C L McCarthy; Y Uchihara; M Vlychou; G Grammatopoulos; N A Athanasou
Journal:  Skeletal Radiol       Date:  2017-03-11       Impact factor: 2.199

Review 6.  Case report: High chromium and cobalt levels in a pregnant patient with bilateral metal-on-metal hip arthroplasties.

Authors:  Juliane Fritzsche; Cornelia Borisch; Christof Schaefer
Journal:  Clin Orthop Relat Res       Date:  2012-06-13       Impact factor: 4.176

Review 7.  Metal-on-metal hip resurfacing arthroplasty: an analysis of safety and revision rates.

Authors:  S Sehatzadeh; K Kaulback; L Levin
Journal:  Ont Health Technol Assess Ser       Date:  2012-08-01

8.  THA using metal-on-metal articulation in active patients younger than 50 years.

Authors:  Christian P Delaunay; François Bonnomet; Philippe Clavert; Philippe Laffargue; Henri Migaud
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

9.  Alumina-on-alumina hip arthroplasty in patients younger than 30 years old.

Authors:  R Nizard; D Pourreyron; A Raould; D Hannouche; L Sedel
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

10.  Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma.

Authors:  Sun Yang; Frank L Meyskens
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.